Itation at 488 nm and emission at 585 nm. MAGPIX program. Phycoerythrin with excitation at 488 nm and emission at 585 nm.Analytica 2021, two, FOR PEER Review Analytica 2021,6The two assays enabled us to profile levels of ARG1 and 3-Deazaneplanocin A Technical Information miR-122 inside a DILI patient. The two Table enabled us to profile levels of ARG1 higher levels inside a DILI patient. As As reported in assays S4, the patient with DILI presentedand miR-122of both ARG1 and reported in Table S4, the patient with DILI presented higher levels of both ARG1 and miR-122, miR-122, whilst, and as anticipated, the no DILI patient did not show important levels of even though, and as miR-122. the no DILI patient didn’t show significant levels of either ARG1 either ARG1 or anticipated,ARG1 and miR-122 levels have been quantified working with the two calibraor miR-122. ARG1 with the information reported in Tables S2 and S3, respectively. Levels of tion curves generatedand miR-122 levels had been quantified applying the two calibration curves generated using the data reported in Tables S2 and S3, respectively. Levels Figure 2. ARG1 and miR-122 were extrapolated and reported in Table S4 and shown inof ARG1 and miR-122 had been extrapolated and reported in Table S4 and shown in Figure two.Figure 2. ARG1 and miR-122 calibration curves with interpolated ARG1 and miR-122 from DILI Figure 2. ARG1 and miR-122 calibration curves with interpolated ARG1 and miR-122 from DILI samples. Error bars ( s.d.) according to triplicate measurements. The error bars are smaller sized than the samples. Error bars ( s.d.) depending on triplicate measurements. The error bars are smaller than the size of some data points. n = three. size of some data points. n = 3.three.2. SeqCOMBO Assay–Analysis of ARG1 and miR-122 Simultaneously three.2. SeqCOMBO Assay–Analysis of ARG1 and miR-122 simultaneously The two individual assays described in Figure 1a,b were Auranofin Inhibitor combined delivering the The two to profile assays described the levels of ARG1 combined delivering the seqCOMBOindividual at the very same time in Figure 1a,b have been and miR-122 inside the serum seqCOMBO a DILI patient. As shown in Figure 3,of ARG1 and miR-122 inside the serum of nine sample of to profile in the same time the levels the seqCOMBO workflow consists sample of asteps. patient. As shown in Figure 3, the seqCOMBO workflow consists of nine main DILI most important actions.seqCOMBO enables profiling levels of ARG1 and miR-122 inside the DILI patient. Because the The seqCOMBO and shown in Figure 2, the patient with DILI inside the DILI patient. reported in Table S4enables profiling levels of ARG1 and miR-122 presented higher levels As reported in Table S4 and shown in Figure 2,anticipated, the noDILI presented high levels of both ARG1 and miR-122, whilst, and because the patient with DILI control didn’t show ofsignificant levels of ARG1 or miR-122. No signal loss was no DILI controlboth protein and each ARG1 and miR-122, whilst, and as expected, the observed when didn’t show significantwere analysed via seqCOMBO at the same time. observed when each protein miRNA levels of ARG1 or miR-122. No signal loss was and miRNA have been analysed by way of seqCOMBO in the same time. seqCOMBO is used, an interTo evaluate how the signal varies when singleplex or CVTo comparegenerated, comparing the MFI signals obtained for individual analysis vs. study was how the signal varies when singleplex or seqCOMBO is used, an interCV study was generated,in Table 1. TheseMFI signals obtainedthe MILIPLEX xMAP kit can seqCOMBO, as shown comparing the results indicate that for individual analysis vs. seqCOMBO, with all the DCL met.